Sex: U
Vaccine: COVID19, COVID19
Symptoms: Pyrexia, Vomiting
Clinical narrative: Mild malaise/feeling sick and no interference with activity; Mild injection site pain and no interference with activity/ Mild injection site tenderness (tender to touch); Mild injection site redness; Mild injection site swelling; Mild fever (100.4 to 101.2 °F); Moderate fatigue with some interference with activity; Mild muscle pain and no interference with activity; Joint pain with some interference with activity; Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting; Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting; This spontaneous case was reported by a non-healthcare professional and describes the occurrence of MALAISE (Mild malaise/feeling sick and no interference with activity), INJECTION SITE PAIN (Mild injection site pain and no interference with activity/ Mild injection site tenderness (tender to touch)), INJECTION SITE ERYTHEMA (Mild injection site redness), INJECTION SITE SWELLING (Mild injection site swelling) and PYREXIA (Mild fever (100.4 to 101.2 °F)) in a  patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced MALAISE (Mild malaise/feeling sick and no interference with activity), INJECTION SITE PAIN (Mild injection site pain and no interference with activity/ Mild injection site tenderness (tender to touch)), INJECTION SITE ERYTHEMA (Mild injection site redness), INJECTION SITE SWELLING (Mild injection site swelling), PYREXIA (Mild fever (100.4 to 101.2 °F)), FATIGUE (Moderate fatigue with some interference with activity), MYALGIA (Mild muscle pain and no interference with activity), ARTHRALGIA (Joint pain with some interference with activity), NAUSEA (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting) and VOMITING (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting). At the time of the report, MALAISE (Mild malaise/feeling sick and no interference with activity), INJECTION SITE PAIN (Mild injection site pain and no interference with activity/ Mild injection site tenderness (tender to touch)), INJECTION SITE ERYTHEMA (Mild injection site redness), INJECTION SITE SWELLING (Mild injection site swelling), PYREXIA (Mild fever (100.4 to 101.2 °F)), FATIGUE (Moderate fatigue with some interference with activity), MYALGIA (Mild muscle pain and no interference with activity), ARTHRALGIA (Joint pain with some interference with activity), NAUSEA (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting) and VOMITING (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature: 100.4 to 101.2 °F.         Patient had experienced Mild injection site pain and no interference with activity (tender to touch), Mild injection site redness, Moderate injection site swelling, Mild fever (100.4 to 101.2 °F), Moderate fatigue with some interference with activity, Mild malaise/feeling sick and no interference with activity, Mild muscle pain and no interference with activity, Joint pain with some interference with activity, Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting, no Headache experienced anytime during the 2 days after COVID-19 vaccination, which occurred Friday, Dec 22, 2023 and Saturday, Dec 23, 2023. No concomitant and treatment medication were reported.   This case was linked to US-MODERNATX, INC.-MOD-2024-755971 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-755971: